| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 65.86% | Needham | $14 → $12 | Reiterates | → Buy |
| 07/13/2023 | 38.22% | B of A Securities | → $10 | Upgrades | Neutral → Buy |
| 05/04/2023 | 24.4% | RBC Capital | → $9 | Reiterates | → Sector Perform |
| 05/04/2023 | 93.5% | Needham | → $14 | Reiterates | → Buy |
| 04/20/2023 | 38.22% | Evercore ISI Group | $13 → $10 | Maintains | Outperform |
| 04/20/2023 | 93.5% | Needham | → $14 | Reiterates | → Buy |
| 03/14/2023 | 38.22% | RBC Capital | → $10 | Reiterates | → Sector Perform |
| 02/22/2023 | 121.15% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 02/22/2023 | 93.5% | Needham | → $14 | Upgrades | Hold → Buy |
| 02/22/2023 | 314.65% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 11/02/2022 | 121.15% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
| 11/02/2022 | 79.68% | RBC Capital | $14 → $13 | Maintains | Sector Perform |
| 08/08/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 93.5% | Barclays | $12 → $14 | Maintains | Equal-Weight |
| 08/05/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 93.5% | Evercore ISI Group | → $14 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 79.68% | Barclays | $22 → $13 | Downgrades | Overweight → Equal-Weight |
| 04/12/2022 | 93.5% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 04/11/2022 | 93.5% | B of A Securities | → $14 | Downgrades | Buy → Neutral |
| 04/11/2022 | 121.15% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 12/10/2021 | 121.15% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 93.5% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 11/04/2021 | 134.97% | Barclays | $21 → $17 | Maintains | Overweight |
| 08/06/2021 | 217.9% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 08/06/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/06/2021 | 121.15% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 08/06/2021 | 190.26% | Barclays | $20 → $21 | Maintains | Overweight |
| 08/06/2021 | 314.65% | HC Wainwright & Co. | $18 → $30 | Maintains | Buy |
| 08/03/2021 | 190.26% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 03/24/2021 | 162.61% | HC Wainwright & Co. | $14 → $19 | Maintains | Buy |
| 01/22/2021 | 24.4% | RBC Capital | $7 → $9 | Maintains | Sector Perform |
| 12/07/2020 | 93.5% | HC Wainwright & Co. | $13 → $14 | Maintains | Buy |
| 11/24/2020 | 65.86% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
| 06/17/2020 | — | BTIG | Initiates Coverage On | → Neutral | |
| 05/05/2020 | -3.25% | Barclays | $4 → $7 | Upgrades | Equal-Weight → Overweight |
| 11/15/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/24/2019 | -37.8% | RBC Capital | $16 → $4.5 | Downgrades | Outperform → Sector Perform |
| 04/02/2019 | 10.57% | Barclays | $6 → $8 | Maintains | Equal-Weight |
| 04/02/2019 | 148.79% | JMP Securities | $16 → $18 | Maintains | Market Outperform |
| 11/16/2018 | 107.33% | Piper Sandler | → $15 | Reinstates | → Overweight |
What is the target price for BioCryst Pharma (BCRX)?
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by Needham on August 3, 2023. The analyst firm set a price target for $12.00 expecting BCRX to rise to within 12 months (a possible 65.86% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by Needham, and BioCryst Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $14.00 to $12.00. The current price BioCryst Pharma (BCRX) is trading at is $7.24, which is out of the analyst's predicted range.